Total Payments
$1.2M
2024 Payments
$200,837
Companies
37
Transactions
1,348
Medicare Patients
1,105
Medicare Billing
$604,238
Payment Breakdown by Category
Other$656,714 (56.4%)
Consulting$236,932 (20.3%)
Travel$125,434 (10.8%)
Research$118,677 (10.2%)
Food & Beverage$27,401 (2.4%)
Education$173.85 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $460,334 | 185 | 39.5% |
| Consulting Fee | $236,932 | 87 | 20.3% |
| Honoraria | $196,380 | 79 | 16.9% |
| Travel and Lodging | $125,434 | 475 | 10.8% |
| Unspecified | $118,677 | 26 | 10.2% |
| Food and Beverage | $27,401 | 490 | 2.4% |
| Education | $173.85 | 6 | 0.0% |
Payments by Type
General
$1.0M
1,322 transactions
Research
$118,677
26 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Alexion Pharmaceuticals, Inc. | $523,011 | 551 | $0 (2024) |
| CSL Behring | $213,607 | 239 | $0 (2024) |
| ARGENX US, INC. | $180,027 | 199 | $0 (2024) |
| Allergan, Inc. | $59,950 | 88 | $0 (2022) |
| UCB SA | $41,902 | 31 | $0 (2023) |
| MITSUBISHI TANABE PHARMA AMERICA, INC. | $33,872 | 56 | $0 (2024) |
| UCB, Inc. | $22,345 | 15 | $0 (2024) |
| Bio Products Laboratory USA, Inc. | $18,055 | 8 | $0 (2023) |
| ABBVIE INC. | $15,858 | 31 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $13,351 | 22 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $200,837 | 207 | Alexion Pharmaceuticals, Inc. ($95,757) |
| 2023 | $168,551 | 213 | ARGENX US, INC. ($88,912) |
| 2022 | $164,654 | 202 | Alexion Pharmaceuticals, Inc. ($57,210) |
| 2021 | $85,605 | 87 | Alexion Pharmaceuticals, Inc. ($28,835) |
| 2020 | $58,309 | 73 | Alexion Pharmaceuticals, Inc. ($25,250) |
| 2019 | $255,277 | 229 | Alexion Pharmaceuticals, Inc. ($146,287) |
| 2018 | $169,954 | 243 | Alexion Pharmaceuticals, Inc. ($89,383) |
| 2017 | $62,146 | 94 | Alexion Pharmaceuticals, Inc. ($38,409) |
All Payment Transactions
1,348 individual payment records from CMS Open Payments — Page 1 of 54
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $34.10 | General |
| Category: Neurology | ||||||
| 12/12/2024 | CSL Behring | Hizentra (Biological) | Travel and Lodging | Cash or cash equivalent | $108.54 | General |
| Category: Immunology | ||||||
| 12/12/2024 | CSL Behring | Hizentra (Biological) | Travel and Lodging | Cash or cash equivalent | $31.08 | General |
| Category: Immunology | ||||||
| 12/11/2024 | CSL Behring | Hizentra (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $750.00 | General |
| Category: Immunology | ||||||
| 12/10/2024 | ARGENX US, INC. | VYVGART (Drug) | Food and Beverage | In-kind items and services | $30.97 | General |
| Category: Immunology | ||||||
| 12/09/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $13,422.50 | General |
| Category: Rare Disease | ||||||
| 12/09/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Travel and Lodging | In-kind items and services | $427.98 | General |
| Category: Rare Disease | ||||||
| 12/04/2024 | CSL Behring | Hizentra (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| Category: Immunology | ||||||
| 12/04/2024 | CSL Behring | Hizentra (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,800.00 | General |
| Category: Immunology | ||||||
| 12/03/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,500.00 | General |
| Category: Neurology | ||||||
| 12/03/2024 | ARGENX US, INC. | VYVGART (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,562.50 | General |
| Category: Immunology | ||||||
| 12/03/2024 | ARGENX US, INC. | VYVGART (Drug) | Travel and Lodging | Cash or cash equivalent | $39.53 | General |
| Category: Immunology | ||||||
| 11/20/2024 | CSL Behring | Hizentra (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,150.00 | General |
| Category: Immunology | ||||||
| 11/20/2024 | ARGENX US, INC. | VYVGART (Drug) | Food and Beverage | In-kind items and services | $30.66 | General |
| Category: Immunology | ||||||
| 11/19/2024 | CSL Behring | Hizentra (Biological) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Immunology | ||||||
| 11/19/2024 | CSL Behring | Hizentra (Biological) | Food and Beverage | In-kind items and services | $25.37 | General |
| Category: Immunology | ||||||
| 11/18/2024 | Janssen Global Services, LLC | — | Consulting Fee | Cash or cash equivalent | $1,800.00 | General |
| 11/16/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Travel and Lodging | Cash or cash equivalent | $53.92 | General |
| Category: Rare Disease | ||||||
| 11/15/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Travel and Lodging | In-kind items and services | $2,398.79 | General |
| Category: Rare Disease | ||||||
| 11/15/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Travel and Lodging | In-kind items and services | $248.40 | General |
| Category: Rare Disease | ||||||
| 11/10/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Travel and Lodging | In-kind items and services | $103.37 | General |
| Category: Rare Disease | ||||||
| 11/08/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Travel and Lodging | In-kind items and services | $154.18 | General |
| Category: Rare Disease | ||||||
| 11/08/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $35.46 | General |
| Category: Rare Disease | ||||||
| 11/07/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Travel and Lodging | In-kind items and services | $4,207.10 | General |
| Category: Rare Disease | ||||||
| 11/07/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Travel and Lodging | Cash or cash equivalent | $45.86 | General |
| Category: Rare Disease | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis | Alexion Pharmaceuticals, Inc. | $99,268 | 11 |
| A PHASE 3, RANDOMIZED, DOUBL-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING EFFICACY AND SAFETY OF ROZANOLIXIZUMAB IN ADULT PATIENTS WITH GENERALIZED MYAS | UCB, Inc. | $8,080 | 1 |
| Phase 3, Multicenter, Randomized, Double-Blind, PBO-Controlled Study of Efficacy, Safety, and Tolerability of Zilucoplan in Subjects with Generalized | UCB, Inc. | $6,020 | 1 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adults With Amyotrophic Lateral Sclerosis | Biogen, Inc. | $1,747 | 1 |
| Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Symptomatic Generalized Myasthenia Gravis | Regeneron Pharmaceuticals, Inc. | $1,322 | 10 |
| Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects with Generalized Myasthenia Gravis | UCB, Inc. | $1,240 | 1 |
| NEW PROTOCOL TO BE ADDED | Takeda Pharmaceuticals U.S.A., Inc. | $1,000 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 221 | 24,091 | $566,723 | $146,784 |
| 2022 | 9 | 193 | 22,408 | $518,851 | $133,940 |
| 2021 | 11 | 313 | 23,017 | $474,745 | $149,180 |
| 2020 | 13 | 378 | 27,328 | $380,673 | $174,334 |
Total Patients
1,105
Total Services
96,844
Medicare Billing
$604,238
Procedure Codes
43
All Medicare Procedures & Services
43 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2023 | 26 | 23,800 | $452,200 | $117,800 | 26.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 41 | 41 | $27,511 | $6,987 | 25.4% |
| 95911 | Nerve conduction, 9-10 studies | Office | 2023 | 25 | 25 | $16,150 | $4,161 | 25.8% |
| 95874 | Needle measurement of electrical activity in muscle with injection of chemical for paralysis of nerve muscle | Office | 2023 | 26 | 65 | $15,340 | $3,886 | 25.3% |
| 64642 | Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, first extremity | Office | 2023 | 17 | 30 | $14,160 | $3,389 | 23.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 18 | 21 | $11,445 | $3,004 | 26.2% |
| 64643 | Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, each additional extremity | Office | 2023 | 11 | 33 | $9,636 | $2,517 | 26.1% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2023 | 22 | 27 | $8,073 | $2,061 | 25.5% |
| 95885 | Needle measurement of electrical activity in arm or leg muscles, limited study | Office | 2023 | 23 | 34 | $6,460 | $1,632 | 25.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 12 | 15 | $5,748 | $1,348 | 23.4% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2022 | 25 | 22,150 | $412,457 | $107,317 | 26.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 32 | 32 | $21,454 | $5,021 | 23.4% |
| 95874 | Needle measurement of electrical activity in muscle with injection of chemical for paralysis of nerve muscle | Office | 2022 | 25 | 65 | $15,544 | $4,050 | 26.1% |
| 95911 | Nerve conduction, 9-10 studies | Office | 2022 | 24 | 24 | $16,368 | $3,877 | 23.7% |
| 64642 | Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, first extremity | Office | 2022 | 15 | 31 | $14,456 | $3,730 | 25.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 19 | 22 | $11,990 | $3,039 | 25.3% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2022 | 23 | 34 | $10,214 | $2,713 | 26.6% |
| 64643 | Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, each additional extremity | Office | 2022 | 12 | 31 | $9,022 | $2,420 | 26.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 18 | 19 | $7,346 | $1,775 | 24.2% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2021 | 30 | 22,601 | $312,785 | $106,470 | 34.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 66 | 81 | $27,913 | $7,363 | 26.4% |
| 95911 | Nerve transmission studies, 9-10 studies | Office | 2021 | 36 | 36 | $25,200 | $6,484 | 25.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 35 | 44 | $21,250 | $5,942 | 28.0% |
| 95886 | Needle measurement and recording of electrical activity of muscles of arm or leg complete study | Office | 2021 | 43 | 63 | $18,469 | $5,073 | 27.5% |
| 95874 | Needle measurement and recording of electrical activity of muscles for guidance with injection of chemical for destruction of muscles | Office | 2021 | 28 | 64 | $15,053 | $4,136 | 27.5% |
About Dr. Tuan Vu, MD
Dr. Tuan Vu, MD is a Neurology healthcare provider based in Tampa, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1679503007.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Tuan Vu, MD has received a total of $1.2M in payments from pharmaceutical and medical device companies, with $200,837 received in 2024. These payments were reported across 1,348 transactions from 37 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($460,334).
As a Medicare-enrolled provider, Vu has provided services to 1,105 Medicare beneficiaries, totaling 96,844 services with total Medicare billing of $604,238. Data is available for 4 years (2020–2023), covering 43 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Tampa, FL
- Active Since 07/03/2006
- Last Updated 04/13/2021
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1679503007
Products in Payments
- Hizentra (Biological) $206,783
- ULTOMIRIS (Biological) $164,367
- SOLIRIS (Drug) $161,240
- VYVGART (Drug) $146,866
- ULTOMIRIS (Drug) $99,268
- BOTOX (Biological) $68,293
- Soliris (Drug) $41,208
- Radicava (Drug) $27,406
- VYVGART HYTRULO (Drug) $25,190
- SOLIRIS (Biological) $10,644
- Gammaplex (Drug) $9,805
- Coagadex (Drug) $8,250
- UPLIZNA (Biological) $7,551
- BOTOX (Drug) $7,105
- Privigen (Biological) $6,806
- RADICAVA (Drug) $6,466
- DYSPORT (Drug) $2,175
- VEOPOZ (Biological) $1,322
- Rystiggo (Drug) $1,316
- OCTAGAM IMMUNE GLOBULIN (HUMAN) (Biological) $1,120
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Tampa
Derrick Robertson, M.d, M.D
Neurology — Payments: $2.3M
Neurology $2.3M
Selim Benbadis, Md, MD
Neurology — Payments: $2.3M
Neurology $2.3M
Dr. Mark Cascione, M.d, M.D
Neurology — Payments: $1.9M
Neurology $1.9M
Robert Hauser, Md, MD
Neurology — Payments: $1.5M
Neurology $1.5M
David Rose, M.d, M.D
Neurology — Payments: $1.5M
Neurology $1.5M
Dr. Katherine Standley, Do, DO
Neurology — Payments: $1.3M
Neurology $1.3M